DLBCL and 24-month EFS
Patients with diffuse large B-cell lymphoma (DLBCL) who achieve event-free survival at 24 months also have overall survival that is equivalent to that of the age- and sex-matched general population.
In this study, patients (n = 767) with newly diagnosed DLBCL treated with immunochemotherapy were prospectively enrolled. At a median follow-up of 60 months, 299 patients had an event and 210 patients had died. A similar result was seen in 820 patients from the Groupe d’Étude des Lymphomes de l’Adulte (GELA) study. For more information, click here.